Diphtheria Clinical Presentation
- Author: Bruce M Lo, MD, CPE, RDMS, FACEP, FAAEM, FACHE; Chief Editor: Jeter (Jay) Pritchard Taylor, III, MD more...
Onset of symptoms of respiratory diphtheria typically follows an incubation period of 2-5 days (range, 1-10 d).[1, 9] Symptoms initially are general and nonspecific, often resembling a typical viral upper respiratory infection (URI). Respiratory involvement typically begins with sore throat and mild pharyngeal inflammation. Development of a localized or coalescing pseudomembrane can occur in any portion of the respiratory tract. The pseudomembrane is characterized by the formation of a dense, gray debris layer composed of a mixture of dead cells, fibrin, RBCs, WBCs, and organisms; the pseudomembrane is shown in the image below.
Removal of the membrane reveals a bleeding, edematous mucosa. The distribution of the membrane varies from local (eg, tonsillar, pharyngeal) to widely covering the entire tracheobronchial tree. The membrane is intensely infectious, and droplet and contact precautions must be followed when examining or caring for infected patients. A combination of cervical adenopathy and swollen mucosa imparts a "bull's neck" appearance to many of the infected patients; this is shown in the image below. The most frequent cause of death is airway obstruction or suffocation following aspiration of the pseudomembrane.
Cutaneous diphtheria is a disease characterized by indolent, nonhealing ulcers covered with a gray membrane. The ulcers are often co-infected with Staphylococcus aureus and group A streptococci. This form of the disease is seen with increasing frequency in poor inner-city dwellers and alcoholics. The lesions of cutaneous diphtheria are infectious, and bacteria from cutaneous lesions have been found to cause pharyngeal infections and thus serve as a reservoir for infection.
Patients with diphtheria may present with the following complaints:
Low-grade fever (rarely >103°F) (50-85%) and chills
Malaise, weakness, prostration
Sore throat (85-90%)
Cervical lymphadenopathy and respiratory tract pseudomembrane formation (about 50%)
Serosanguineous or seropurulent nasal discharge, white nasal membrane
Hoarseness, dysphagia (26-40%)
Dyspnea, respiratory stridor, wheezing, cough
Respiratory diphtheria may quickly progress to respiratory failure due to airway obstruction or aspiration of pseudomembrane into the tracheobronchial tree.
Cutaneous diphtheria often develops at a site of previous trauma or a primary dermatologic disease. It follows an indolent course, typically lasting weeks to months. Occasionally, it may cause respiratory diphtheria.
General: Patient has a low-grade fever but is toxic in appearance, and also may have a swollen neck.
Patients may present with general symptoms of fever, halitosis, tachycardia, and anxiety.
Tonsils and pharynx: Pharyngeal erythema and edema, thick, gray, leathery membrane variably covers the tonsils, soft palate, oropharynx, nasopharynx, and uvula. Attempts at scraping the pseudomembrane causes bleeding of the underlying mucosa.
Neck: Extensive anterior and submandibular cervical lymphadenopathy imparts a bull's neck appearance. The patient may hold his or her head in extension. It can occasionally also be associated with dysphonia.
Respiratory distress manifesting as stridor, wheezing, cyanosis, accessory muscle use, and retractions.
Cardiac toxicity typically occurs after 1-2 weeks of illness following improvement in the pharyngeal phase of the disease. It may manifest as follows:
Atrioventricular blocks, ST-T wave changes, and various dysrhythmias may be evident.
Neurologic toxicity is proportional to the severity of the pharyngeal infection. Most patients with severe disease develop neuropathy. Deficits include the following:
Cranial nerve deficits including oculomotor, ciliary paralysis, facial, and pharyngeal, or laryngeal nervous dysfunction.
Occasionally, a stocking and glove peripheral sensory neuropathy pattern can be observed.
Most C diphtheriae associated neurologic dysfunction eventually resolves.
Peripheral neuritis develops anywhere from 10 days to 3 months after the onset of pharyngeal disease. It manifests initially as a motor defect of the proximal muscle groups in the extremities extending distally. Various degrees of dysfunction exist, ranging from diminished DTRs to paralysis. 
Other systems involvement: Diphtheria is occasionally seen in the female genital tract, conjunctivae, or ear.
Invasive disease may manifest in multiple organ system disease, though this is rare. [1, 3]
Cutaneous diphtheria begins as a painful lesion resembling an erythematous pustule, which breaks down to form an ulcer covered with a gray membrane. [4, 16]
The following factors may predispose to diphtheria infection:
Incomplete or absent immunization, which is especially important in the adult population, and as well the pediatric population in underdeveloped countries, may predispose to infection. In some cases, immunity does not prevent infection but lessens the severity of the disease. 
Antitoxin titers decrease over time and immunity wanes, thus older people who have not received booster vaccination are more susceptible to contract the disease from carriers. Studies suggest if titer level is greater than 0.1 UI/mL, then an individual is characterized as immune from infection.
Low herd immunity, possibly leading to increasing prevalence of diphtheria infections
Travel to endemic areas or regions with current epidemics
Immunocompromised states - Due to pharmacologic immune suppression, disease states including HIV, or relative compromise such as from diabetes or alcoholism
Low socioeconomic status
Large-scale population movements - Implicated in the spread of the epidemic in the Newly Independent States of the former Soviet Union 
Poor healthcare care system infrastructure
Overcrowding - Military barracks, homeless shelters, jails
Domestic animals such as cats may act as reservoir for human infection. 
Chen RT, Broome CV, Weinstein RA. Diphtheria in the United States, 1971-81. Am J Public Health. 1985 Dec. 75(12):1393-7. [Medline].
Dale DC, ed. 16 Infections Due to Gram-Positive Bacilli. Infectious Diseases: The Clinician's Guide to Diagnosis, Treatment, and Prevention. WebMD Corporation; 2007.
Mattos-Guaraldi AL, Sampaio JL, Santos CS, Pimenta FP, Pereira GA, Pacheco LG, et al. First detection of Corynebacterium ulcerans producing a diphtheria-like toxin in a case of human with pulmonary infection in the Rio de Janeiro metropolitan area, Brazil. Mem Inst Oswaldo Cruz. 2008 Jun. 103(4):396-400. [Medline]. [Full Text].
Bonmarin I, Guiso N, Le Fleche-Mateos A, Patey O, Patrick AD, Levy-Bruhl D. Diphtheria: a zoonotic disease in France?. Vaccine. 2009 Jun 24. 27(31):4196-200. [Medline].
Harnisch JP, Tronca E, Nolan CM, Turck M, Holmes KK. Diphtheria among alcoholic urban adults. A decade of experience in Seattle. Ann Intern Med. 1989 Jul 1. 111(1):71-82. [Medline].
Centers for Disease Control and Prevention. FDA approval of expanded age indication for a tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine. MMWR Morb Mortal Wkly Rep. 2009 Apr 17. 58(14):374-5. [Medline].
Webb TR, Cross SH, McKie L, Edgar R, Vizor L, Harrison J, et al. Diphthamide modification of eEF2 requires a J-domain protein and is essential for normal development. J Cell Sci. 2008 Oct 1. 121:3140-5. [Medline]. [Full Text].
CDC. Summary of notifiable diseases--United States, 2001. MMWR Morb Mortal Wkly Rep. 2003 May 2. 50(53):i-xxiv, 1-108. [Medline].
Mattos-Guaraldi AL, Moreira LO, Damasco PV, Hirata Júnior R. Diphtheria remains a threat to health in the developing world--an overview. Mem Inst Oswaldo Cruz. 2003 Dec. 98(8):987-93. [Medline]. [Full Text].
Vitek CR, Wharton M. Diphtheria in the former Soviet Union: reemergence of a pandemic disease. Emerg Infect Dis. 1998 Oct-Dec. 4(4):539-50. [Medline].
de Benoist AC, White JM, Efstratiou A, et al. Imported cutaneous diphtheria, United Kingdom. Emerg Infect Dis. 2004 Mar. 10(3):511-3. [Medline].
Wagner KS, White JM, Lucenko I, Mercer D, Crowcroft NS, Neal S. Diphtheria in the postepidemic period, Europe, 2000-2009. Emerg Infect Dis. 2012 Feb. 18(2):217-25. [Medline].
Dallman T, Neal S, Green J, Efstratiou A. Development of an online database for diphtheria molecular epidemiology under the remit of the DIPNET project. Euro Surveill. 2008 May 8. 13(19):[Medline].
Patel UV, Patel BH, Bhavsar BS. A Retrospective Study of Diphtheria Cases Rajkot, Gujarat. Indian Journal of Community Medicine. 2004. XXIX, No 4:
Mandell, Bennett, Dolin. Corynebacterium diphtheriae. Principles and Practice of Infectious Diseases. 2005. 2457-2464.
Murphy TV, Slade BA, Broder KR, Kretsinger K, Tiwari T, Joyce PM, et al. Prevention of pertussis, tetanus, and diphtheria among pregnant and postpartum women and their infants recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008 May 30. 57:1-51. [Medline]. [Full Text].
Havaldar PV, Sankpal MN, Doddannavar RP. Diphtheritic myocarditis: clinical and laboratory parameters of prognosis and fatal outcome. Ann Trop Paediatr. 2000 Sep. 20(3):209-15. [Medline].
Muttaiyah S, Best EJ, Freeman JT, Taylor SL, Morris AJ, Roberts SA. Corynebacterium diphtheriae endocarditis: a case series and review of the treatment approach. Int J Infect Dis. 2011 Sep. 15(9):e584-8. [Medline].
Holmes RK. Diphtheria, other corynebacterial infections and Anthrax. Principles of Internal Medicine. 2001. 1:909-912.
Dittmann S, Wharton M, Vitek C, et al. Successful control of epidemic diphtheria in the states of the Former Union of Soviet Socialist Republics: lessons learned. J Infect Dis. 2000 Feb. 181 Suppl 1:S10-22. [Medline].
Lakkireddy DR, Kondur AK, Chediak EJ. Cardiac troponin I release in non-ischemic reversible myocardial injury from acute diphtheric myocarditis. Int J Cardiol. 2005 Feb 15. 98(2):351-4. [Medline].
Lumio JT, Groundstroem KW, Melnick OB, Huhtala H, Rakhmanova AG. Electrocardiographic abnormalities in patients with diphtheria: a prospective study. Am J Med. 2004 Jan 15. 116(2):78-83. [Medline].
Centers for Disease Control and Prevention. Licensure of a diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine and guidance for use as a booster dose. MMWR Morb Mortal Wkly Rep. 2008 Oct 3. 57(39):1078-9. [Medline]. [Full Text].
Centers for Disease Control and Prevention. National, state, and urban area vaccination coverage among children aged 19-35 months--United States, 2004. MMWR Morb Mortal Wkly Rep. 2005 Jul 29. 54(29):717-21. [Medline].
Centers for Disease Control and Prevention. Vaccination coverage among adolescents aged 13-17 years - United States, 2007. MMWR Morb Mortal Wkly Rep. 2008 Oct 10. 57(40):1100-3. [Medline]. [Full Text].
Centers for Disease Control and Prevention. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine in adults aged 65 years and older - Advisory Committee on Immunization Practices (ACIP), 2012. MMWR Morb Mortal Wkly Rep. 2012 Jun 29. 61(25):468-70. [Medline].
Centers for Disease Control and Prevention. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) in pregnant women and persons who have or anticipate having close contact with an infant aged 1111111111MMWR Morb Mortal Wkly Rep</i>. 2011 Oct 21. 60(41):1424-6. [Medline].
Center for Disease Control and Prevention. CDC Advisory Committee for Immunization Practices Recommends Tdap Immunization for Pregnant Women. Available at http://www.cdc.gov/media/releases/2012/a1024_Tdap_immunization.html. Accessed: November 19, 2012.
Dajani NA, Scheifele D. How long can we expect pertussis protection to last after the adolescent booster dose of tetanus-diphtheria-pertussis (Tdap) vaccines?. Paediatr Child Health. 2007 Dec. 12(10):873-4. [Medline]. [Full Text].
Bronson-Lowe D, Anderson SM. Effects of a minimum interval immunization schedule for diphtheria and tetanus toxoids and acellular pertussis vaccination during a pertussis outbreak. Arch Pediatr Adolesc Med. 2009 May. 163(5):417-21. [Medline].
Jayashree M, Shruthi N, Singhi S. Predictors of outcome in patients with diphtheria receiving intensive care. Indian Pediatr. 2006 Feb. 43(2):155-60. [Medline].
Lurie P, Stafford H, Tran P. Fatal respiratory diphtheria in a U.S. traveler to Haiti--Pennsylvania, 2003. MMWR Morb Mortal Wkly Rep. 2004 Jan 9. 52(53):1285-6. [Medline].
Maksimova NM, Markina SS, Iatskovskii KA, Cherkasova VV, Lazikova GF, Koshkina NA. [Immunization of adult population of Russia against diphtheria in 2006-2007]. Zh Mikrobiol Epidemiol Immunobiol. 2008 Nov-Dec. 27-31. [Medline].
Prasad KC, Karthik S, Prasad SC. A comprehensive study on lesions of the pinna. Am J Otolaryngol. 2005 Jan-Feb. 26(1):1-6. [Medline].
Zasada AA, Zaleska M, Podlasin RB, Seferynska I. The first case of septicemia due to nontoxigenic Corynebacterium diphtheriae in Poland: case report. Ann Clin Microbiol Antimicrob. 2005 May 5. 4:8. [Medline].